Literature DB >> 23430807

Sight-threatening phenylketonuric encephalopathy in a young adult, reversed by diet.

S Rubin1, A L Le Piffer, M B Rougier, M N Delyfer, J F Korobelnik, I Redonnet-Vernhet, C Marchal, C Goizet, S Mesli, C Gonzalez, H Gin, V Rigalleau.   

Abstract

Phenylketonuria (PKU) leads to severe neurological disorders in childhood, shunned by the diet. The long-term prognosis after diet diversification at adolescence is uncertain. We report a case of cortical blindness in a young patient regressive 1 month after the diet was resumed.Mr M., 25 years old, had PKU detected at birth. He maintained good serum levels of Phenylalanine (Phe) (120-300 μmol/L) during childhood and got a normal intellectual development. During adolescence he diversified his diet but maintained low meat and fish intake; Phe was ~1,200 μmol/L with no symptoms. In 2009, the patient stopped the low-Phe amino acid substitutes due to weariness. On June 27, 2011, he consulted for a decrease of visual acuity progressing for 6 months. Ophthalmologic examination found that visual acuity was 2/10 in two eyes associated to a central visual field defect. The visual evoked potentials were altered. MRI showed bilateral and symmetric occipital FLAIR hyperintensities. On admission in the Nutrional Unit on June 29, 2011, blood pressure was 120/70 mmHg, there was no other neurological abnormality. Phe was at 1,512 μmol/L, and not responsive to BH4. He was then treated with a very low-Phe diet with an amino acid substitute, and he obtained Phe between 120 and 300 μmol/L. Visual acuity was suddenly restored on August 1, 2011, with a dramatic attenuation of the MRI hyperintensities.Our observation shows that the withdrawal of the diet and substitutes exposes to serious neurological complications in adults that may reverse with a fast nutritional support.

Entities:  

Year:  2013        PMID: 23430807      PMCID: PMC3755574          DOI: 10.1007/8904_2012_207

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  7 in total

Review 1.  Phenylketonuria.

Authors:  Nenad Blau; Francjan J van Spronsen; Harvey L Levy
Journal:  Lancet       Date:  2010-10-23       Impact factor: 79.321

Review 2.  Pathogenesis of cognitive dysfunction in phenylketonuria: review of hypotheses.

Authors:  M J de Groot; M Hoeksma; N Blau; D J Reijngoud; F J van Spronsen
Journal:  Mol Genet Metab       Date:  2010       Impact factor: 4.797

Review 3.  White matter pathology in phenylketonuria.

Authors:  Peter J Anderson; Vincenzo Leuzzi
Journal:  Mol Genet Metab       Date:  2010       Impact factor: 4.797

4.  [Phenylketonuria with adult-onset neurological manifestation].

Authors:  K Ishimaru; N Tamasawa; M Baba; M Matsunaga; K Takebe
Journal:  Rinsho Shinkeigaku       Date:  1993-09

5.  Characterization of white matter alterations in phenylketonuria by magnetic resonance relaxometry and diffusion tensor imaging.

Authors:  Peter Vermathen; Laure Robert-Tissot; Joachim Pietz; Thomas Lutz; Chris Boesch; Roland Kreis
Journal:  Magn Reson Med       Date:  2007-12       Impact factor: 4.668

6.  Neurological deterioration in young adults with phenylketonuria.

Authors:  A J Thompson; I Smith; D Brenton; B D Youl; G Rylance; D C Davidson; B Kendall; A J Lees
Journal:  Lancet       Date:  1990-09-08       Impact factor: 79.321

7.  Golgi-Kopsch silver study of the brain of a patient with untreated phenylketonuria, seizures, and cortical blindness.

Authors:  S Kornguth; E Gilbert-Barness; E Langer; L Hegstrand
Journal:  Am J Med Genet       Date:  1992-11-01
  7 in total
  3 in total

Review 1.  Genetic etiology and clinical challenges of phenylketonuria.

Authors:  Nasser A Elhawary; Imad A AlJahdali; Iman S Abumansour; Ezzeldin N Elhawary; Nagwa Gaboon; Mohammed Dandini; Abdulelah Madkhali; Wafaa Alosaimi; Abdulmajeed Alzahrani; Fawzia Aljohani; Ehab M Melibary; Osama A Kensara
Journal:  Hum Genomics       Date:  2022-07-19       Impact factor: 6.481

Review 2.  The complete European guidelines on phenylketonuria: diagnosis and treatment.

Authors:  A M J van Wegberg; A MacDonald; K Ahring; A Bélanger-Quintana; N Blau; A M Bosch; A Burlina; J Campistol; F Feillet; M Giżewska; S C Huijbregts; S Kearney; V Leuzzi; F Maillot; A C Muntau; M van Rijn; F Trefz; J H Walter; F J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2017-10-12       Impact factor: 4.123

Review 3.  Phenylketonuria.

Authors:  Francjan J van Spronsen; Nenad Blau; Cary Harding; Alberto Burlina; Nicola Longo; Annet M Bosch
Journal:  Nat Rev Dis Primers       Date:  2021-05-20       Impact factor: 52.329

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.